Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Ziprasidone in the Psychosis Prodrome (ZIP)

This study has been completed.
Information provided by (Responsible Party):
Yale University Identifier:
First received: March 6, 2008
Last updated: September 6, 2016
Last verified: September 2016

March 6, 2008
September 6, 2016
March 2008
November 2012   (Final data collection date for primary outcome measure)
Conversion to Psychosis [ Time Frame: 6 months ]
Conversion to psychosis according to the SIPS require psychotic symptom severity ratings in the frankly psychotic range, along with meeting persistence or urgency criteria.
Conversion to Psychosis [ Time Frame: 6 months ]
Complete list of historical versions of study NCT00635700 on Archive Site
Improvement SOPS Total Score [ Time Frame: 8 weeks ]
Same as current
Not Provided
Not Provided
Ziprasidone in the Psychosis Prodrome
Ziprasidone vs Placebo in the Prevention of Psychosis Among Symptomatic Adolescents and Young Adults at Prodromal Risk
This study aims to determine whether ziprasidone is superior to placebo over 24 weeks for patients with the psychosis prodrome.
Not Provided
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Psychosis Prodrome
  • Drug: ziprasidone
    20-160 mg/d
    Other Name: Geodon
  • Drug: placebo
  • Experimental: 1
    Intervention: Drug: ziprasidone
  • Placebo Comparator: 2
    Intervention: Drug: placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
November 2012
November 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • SIPS criteria for psychosis prodrome
  • clinically referred

Exclusion Criteria:

  • prolonged QTc
  • history of syncope
Sexes Eligible for Study: All
16 Years to 40 Years   (Child, Adult)
Contact information is only displayed when the study is recruiting subjects
United States,   Canada
Not Provided
Not Provided
Not Provided
Yale University
Yale University
Not Provided
Principal Investigator: Scott W Woods, MD Yale University
Yale University
September 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP